NUPLAZID® (pimavanserin) is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Acadia Connect® will liaise with the patient's insurance regarding any prior approvals, and they'll also communicate with the patient and family members about the cost and the delivery of medication.” —Dr. Bahroo
Fill out the Treatment and Service Request Form to prescribe NUPLAZID and enroll your patients in Acadia Connect.
Support for your practice and the families you care for
Acadia Connect helps ensure that it’s easy for your patients or residents to start and continue taking NUPLAZID. We’re here to support you and those prescribed NUPLAZID with access, insurance, affordability, and prescription assistance. Learn more
Prescribing through an EHR system
NUPLAZID can only be filled through the following in-network pharmacies:
- Walgreens Specialty Pharmacy
- Walmart Specialty Pharmacy
- CenterWell Specialty Pharmacy
- CVS Specialty Pharmacy
- Accredo
To get your patients the benefits of Acadia Connect, complete the Treatment & Service Request Form when e-prescribing.
Ordering at a long-term care facility
Simply follow the current prescribing protocol for your facility to order NUPLAZID.
NUPLAZID is accessible and affordable
With comprehensive coverage and financial assistance support from Acadia Connect, your patient’s NUPLAZID prescription may be more affordable than you think.
9 in 10 patients pay less than $10 as final out-of-pocket costs for their prescription*
100% of Medicare Part D plans cover NUPLAZID†
$0 co-pay for qualifying commercially covered patients‡
*Around 10% of patients may pay more than $10 for their prescription. As reported by 4 specialty pharmacy organizations; Q1 to Q2 2023 data.
†Managed Markets Insight & Technology. Formulary Lookup website, https://formularylookup.com. Accessed October 31, 2023.
‡Acadia Connect patient eligibility and terms and conditions apply.
Enroll your patient or resident now
Complete the Treatment & Service Request Form to prescribe NUPLAZID, request a free 14-day supply§ (if applicable), and enroll your patient or resident in Acadia Connect. You can fill out the form online at acadiaconnect.com, or click the button below to download a PDF and submit via fax or email.
Download Treatment & Service Request Form§Appropriate patients must be enrolled in Acadia Connect to be eligible for the free 14-day supply. Acadia Connect patient eligibility and terms and conditions apply.
Your office will be paired with a Patient Access Manager (PAM) to assist you as your patients start and continue treatment.
Your patients will be assigned a dedicated Care Coordinator they can turn to for help with insurance coverage, financial assistance, and prescription delivery.
ICD-10 diagnostic codes for Parkinson’s disease (PD) psychosis
Your patient with PD-related hallucinations and delusions may need prior authorization to get coverage for NUPLAZID. View classification codes below. All coding decisions are ultimately the responsibility of each prescribing healthcare provider.
Coding combinations recognized for PD psychosis include any of the G20 (PD) sub-codes (G20.A1, G20.A2, G20.B1, G20.B2) plus one of the following ICD-10 codes1,2:
- F06.0 Psychotic disorder with hallucinations due to known physiological condition
- F06.2 Psychotic disorder with delusions due to known physiological condition
99% of prior authorizations on Medicare Part D plans only require a basic confirmation of diagnosis and/or a specialty prescriber.||
|| Formulary data current as of October 2023. Formulary status is subject to change. Please check with health plan to confirm.
Tools to assist you
These simple tools were created to help you enroll your patients in Acadia Connect and get them started on their prescription medication.
Formulary lookup
See if your patient’s insurance will cover NUPLAZID.
This information is intended as a guide. Coverage and costs may differ between private and government insurance plans, and are subject to change. Please check with the health plan to confirm coverage for individual patients.
PAM tool
Your PAM can assist with access or affordability issues and keep you informed if there's an interruption to the treatment regimen you prescribed.
Letter forms
Find templates in the event your patients need a letter of appeal or letter of medical necessity. PDF versions of these templates are also available for download.
Questions? Connect with an Acadia Connect representative.
1-844-737-2223
Monday through Friday
8:00 AM-8:00 PM ET
Get helpful resources from Acadia Connect for you and your patients.
IMPORTANT SAFETY INFORMATION and INDICATION
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease.
- Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
-
Warnings and Precautions: QT Interval Prolongation
-
NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
-
NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
-
- Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
-
Drug Interactions:
-
Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
-
Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.
-
Indication NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
Dosage and Administration Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.
NUPLAZID is available as 34 mg capsules and 10 mg tablets.
Please read the full Prescribing Information, including Boxed WARNING.
References:
- Centers for Medicare & Medicaid Services. ICD-10-CM Tabular List of Diseases and Injuries. Baltimore, MD: US Dept of Health and Human Services; 2023.
- Centers for Medicare & Medicaid Services. ICD-10-CM Tabular List of Diseases and Injuries 2024 Addenda. Baltimore, MD: US Dept of Health and Human Services; 2024.